Burimamide
| Burimamide | |
|---|---|
 |
|
|
1-[4-(1H-Imidazol-5-yl)butyl] -3-methylthiourea |
|
| Identifiers | |
| CAS number | 34970-69-9 |
| PubChem | 3032915 |
| ChemSpider | 2297780  |
| UNII | TN5A4OD2TV |
| KEGG | C07448 |
| ChEMBL | CHEMBL12160 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C9H16N4S |
| Molar mass | 212.32 g/mol |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references |
Burimamide is an antagonist at the H2 and H3 histamine receptors. It is largely inactive as an H2 antagonist at physiological pH,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of buriamide ultimately led to the development of cimetidine (Tagamet).[2]
[edit] See also
[edit] References
- ^ Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0.
- ^ a b "Tagamet: A medicine that changed people's lives". American Chemical Society. 2004. http://acswebcontent.acs.org/landmarks/tagamet/tagamet.html. Retrieved 2009-09-06.
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
